- Home
- ATOS vs GDL Comparison
ATOS vs GDL Comparison
Compare ATOS & GDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- GDL
- Stock Information
- Founded
- ATOS 2009
- GDL 2006
- Country
- ATOS United States
- GDL United States
- Employees
- ATOS N/A
- GDL N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- GDL Investment Managers
- Sector
- ATOS Health Care
- GDL Finance
- Exchange
- ATOS Nasdaq
- GDL Nasdaq
- Market Cap
- ATOS 107.2M
- GDL 93.3M
- IPO Year
- ATOS 2012
- GDL N/A
- Fundamental
- Price
- ATOS $0.84
- GDL $8.62
- Analyst Decision
- ATOS Strong Buy
- GDL
- Analyst Count
- ATOS 3
- GDL 0
- Target Price
- ATOS $6.17
- GDL N/A
- AVG Volume (30 Days)
- ATOS 483.0K
- GDL 11.2K
- Earning Date
- ATOS 11-11-2025
- GDL 01-01-0001
- Dividend Yield
- ATOS N/A
- GDL 6.02%
- EPS Growth
- ATOS N/A
- GDL N/A
- EPS
- ATOS N/A
- GDL N/A
- Revenue
- ATOS N/A
- GDL N/A
- Revenue This Year
- ATOS N/A
- GDL N/A
- Revenue Next Year
- ATOS N/A
- GDL N/A
- P/E Ratio
- ATOS N/A
- GDL N/A
- Revenue Growth
- ATOS N/A
- GDL N/A
- 52 Week Low
- ATOS $0.55
- GDL $7.65
- 52 Week High
- ATOS $1.66
- GDL $8.13
- Technical
- Relative Strength Index (RSI)
- ATOS 60.84
- GDL 67.58
- Support Level
- ATOS $0.81
- GDL $8.56
- Resistance Level
- ATOS $0.80
- GDL $8.64
- Average True Range (ATR)
- ATOS 0.03
- GDL 0.04
- MACD
- ATOS 0.01
- GDL 0.01
- Stochastic Oscillator
- ATOS 92.67
- GDL 88.09
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.